Viskase Holdings, Inc.
VISK · OTCMCIK 727510fmd_0D849SSGXZEDNTTSR8HNSSV0TPManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 8 | 7 | 0 | 0 | 1 | 0 | – | 0 | – |
| Research and development | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 |
| Operating income | – | – | – | (1) | (1) | (0) | (1) | (1) | (1) | (5) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | 7 | 7 | 6 | (1) | (1) | (0) | (0) | 1 | 1 | (3) |
| Income tax expense | 8 | 2 | 0 | 0 | 0 | 0 | (0) | (0) | 0 | 0 |
| Net income from continuing operations | (1) | 5 | 6 | (1) | (1) | (0) | (0) | 1 | 1 | (3) |
| Net income | (1) | 5 | 6 | (1) | (1) | (0) | (0) | 1 | 1 | (3) |
| Net income to common shareholders | (1) | 5 | – | (1) | (2) | (2) | (1) | 0 | (0) | (6) |